KAT6A inhibitor-loaded and anti-PD-L1-coated manganese metal–organic framework nanoplatform for enhanced colorectal cancer immunotherapy via cGAS-STING activation
作者
Helei Wang,Chao Ji,Cheng Xie,Zongyang Li,Hongqiao Cai
Colorectal cancer immunotherapy remains limited by insufficient innate immune activation, poor tumor immune infiltration, and resistance to immune checkpoint blockade. Herein, we developed a KAT6A inhibitor-loaded and anti-PD-L1-coated manganese metal-organic framework (MnMOF) nanoplatform for enhanced colorectal cancer immunotherapy through coordinated cGAS-STING activation and PD-L1 blockade. The KAT6A inhibitor (Ki) PF-9363 was loaded into MnMOF, followed by surface modification with anti-PD-L1 antibody to obtain Ki@MnMOF@P. The nanoplatform exhibited efficient Ki loading, pH-responsive drug release, and retained PD-L1 blocking activity. In vitro, Ki@MnMOF@P showed enhanced cellular uptake and selective cytotoxicity against HCT116 cells while maintaining low toxicity toward normal colonic epithelial NCM460 cells. In a CT26 colorectal tumor-bearing mouse model, systemic administration of Ki@MnMOF@P significantly inhibited tumor growth, reduced tumor weight, and prolonged survival. Moreover, Ki@MnMOF@P achieved favorable tumor accumulation without obvious systemic toxicity. Mechanistically, Ki@MnMOF@P suppressed KAT6A expression, promoted cGAMP production, enhanced cGAS expression, and increased STING phosphorylation in tumor tissues. Besides, the nanoplatform remodeled the tumor immune microenvironment by elevating IFN-β, CXCL10, TNF-α, IL-6, and IFN-γ levels and increasing CD8 + and CD4 + T-cell infiltration. These findings demonstrate that Ki@MnMOF@P integrates KAT6A inhibitor and manganese-mediated cGAS-STING activation and anti-PD-L1-mediated checkpoint blockade, providing a promising nanomedicine strategy for colorectal cancer immunotherapy.